白藜芦醇抑制A549人肺腺癌细胞增殖与IGF-ⅠR的关系  

Correlation between inhibitory effect of resveratrol on proliferation of A549 human lung andenocarcinoma cells and IGF-ⅠR

作　　者：朱剑武[1] 夏蕾[1] 杨剑[2] 罗维[1] 李娟[1] 周芊[1] 曾林立[1] 王东[1] 杨镇洲[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所肿瘤中心,重庆400042 [2]第三军医大学大坪医院野战外科研究所营养科,重庆400042

出　　处：《第三军医大学学报》2011年第24期2567-2570,共4页Journal of Third Military Medical University

基　　金：国家自然科学基金(30970865);重庆市自然科学基金(CSTC2010BB5198);第三军医大学回国人员启动基金(2009XHG17)~~

摘　　要：目的探讨白藜芦醇对人肺腺癌A549细胞增殖的抑制效应及其与IGF-ⅠR的关系。方法以人肺腺癌A549细胞株为研究对象,采用MTT方法测定细胞增殖,用RT-PCR与免疫印迹方法测定IGF-Ⅰ受体mRNA与蛋白表达水平。结果 2.5～15 nmol/L IGF-Ⅰ可显著促进A549细胞增殖(P<0.05),给予12.5、25.0、50μmol/L白藜芦醇对A549细胞增殖具有明显抑制作用(P<0.05)。白藜芦醇(6.25～50μmol/L)与10 nmol/L IGF-Ⅰ共作用于A549细胞,均可抑制IGF-Ⅰ的促A549细胞增殖作用,其中尤以25、50μmol/L白藜芦醇的抑制增殖作用显著(P<0.05),白藜芦醇可有效降低IGF-ⅠR mRNA与蛋白表达。结论白藜芦醇可通过降低IGF-ⅠR mRNA与蛋白表达有效抑制IGF-Ⅰ介导的A549肺癌细胞增殖。Objective To study the correlation between inhibitory effect of resveratrol on proliferation of A549 human lung adenocarcinoma cells and IGF-ⅠR.Methods Proliferation of A549 human lung andenocarcinoma cells was detected by methyl thiazolyl tetrazolium（MTT） assay.Expression level of IGF-ⅠR mRNA and protein was measured by RT-PCR and Western blotting,respectively.Results IGF-Ⅰ at the concentration of 2.5 to 15 nmol/L significantly increased the proliferation of A549 human lung andenocarcinoma cells（P0.05） and resveratrol at the concentrations of 12.5,25.0 and 50 μmol/L remarkably inhibited the proliferation of A549 human lung andenocarcinoma cells（P0.05）.Combined resveratrol（6.25 to 50 μmol/L） and IGF-Ⅰ（10 nmol/L） could inhibit the IGF-ⅠR-induced proliferation of A549 human lung andenocarcinoma cells,especially at the concentrations of 25.0 and 50.0 μmol/L（P0.05）.Resveratrol could effectively down-regulate the expression of IGF-ⅠR mRNA and protein.Conclusion Resveratrol can effectively inhibit the IGF-ⅠR-induced proliferation of A549 human lung adenocarcinoma cells by down-regulating the expression of IGF-ⅠR mRNA and protein.

关 键 词：白藜芦醇 胰岛素样生长因子-1 胰岛素样生长因子-1受体 人肺腺癌细胞A549 

分 类 号：R730.23[医药卫生—肿瘤] R734.2[医药卫生—临床医学]